Obesity Drug Clinical Trial Results Tracker (2026)

Last checked: 19 October 2026. This 2026 obesity-drug clinical trial results tracker covers retatrutide (TRIUMPH), CagriSema (REDEFINE), survodutide (SYNCHRONIZE) and petrelintide (ZUPREME). It follows reported results and development milestones, keeping peer-reviewed findings, sponsor topline announcements, registry records and regulatory decisions separate. It is not a treatment recommendation and does not provide dosing or purchasing guidance.

Latest obesity-drug trial results at a glance

Retatrutide: Phase 3 program has produced multiple positive readouts

Retatrutide is an investigational GIP, GLP-1 and glucagon receptor agonist. In May 2026, Eli Lilly reported that the 12 mg arm of TRIUMPH-1 produced a mean body-weight reduction of 28.3% at 80 weeks in adults with obesity or overweight without diabetes. Lilly later reported positive results from TRIUMPH-2 and TRIUMPH-3, including mean reductions of up to 20.8% and 22.6% respectively in the populations studied.

These are important Phase 3 signals, but they should still be read in context: trial populations, estimands, discontinuation handling and dose arms differ. Lilly has said it plans a US regulatory submission in 2027. In Australia, the TGA stated in September 2026 that retatrutide remains in human clinical trials and has not been approved by the TGA or a comparable international regulator. Primary sources: Lilly TRIUMPH-1 release, Lilly TRIUMPH-2/-3 release, ClinicalTrials.gov TRIUMPH-1 record, and the TGA September 2026 safety alert.

CagriSema: strong weight-loss signal, but the head-to-head result matters

For the two published placebo-controlled obesity studies, read REDEFINE 1 and REDEFINE 2 evidence explained. It separates populations and treatment-policy estimates; these studies are distinct from later active-comparator programmes.

CagriSema combines cagrilintide with semaglutide. Novo Nordisk reported in September 2026 that REDEFINE 9 achieved 21% mean weight loss versus placebo at week 68. Earlier in 2026, however, the open-label REDEFINE 4 trial reported 23% mean weight loss for CagriSema while failing its primary endpoint of showing non-inferiority to tirzepatide 15 mg at week 84. That distinction is important: a large absolute weight-loss percentage does not automatically mean a trial met its predefined statistical objective.

Primary sources: Novo Nordisk September 2026 REDEFINE 9 / REIMAGINE 5 update and Novo Nordisk REDEFINE 4 headline results.

Survodutide: Phase 3 results broaden the non-semaglutide pipeline

Survodutide is a glucagon/GLP-1 receptor dual agonist developed by Boehringer Ingelheim and licensed from Zealand Pharma. In SYNCHRONIZE-2, Boehringer reported weight reduction of up to 13.1% versus 3.1% with placebo after 76 weeks in people with obesity or overweight and type 2 diabetes, alongside improvements in glycaemic measures. The company reported that detailed results were presented at EASD 2026 and published in the New England Journal of Medicine.

Source: Boehringer Ingelheim SYNCHRONIZE-2 Phase 3 update.

Petrelintide: an amylin strategy enters registrational Phase 3

Petrelintide is a long-acting amylin analogue being developed by Zealand Pharma with Roche. Zealand reported the initiation of the registrational ZUPREME Phase 3 program in September 2026, followed by a positive Phase 2 ZUPREME-2 topline update in October. The program is notable because it tests a non-incretin-led obesity strategy rather than another GLP-1-only approach.

Sources: Zealand Pharma 2026 newsroom and the petrelintide development page. Zealand states that petrelintide remains investigational and has not been approved for marketing by any regulatory authority.

Australian regulatory context

Trial success and Australian approval are separate questions. The TGA has repeatedly warned that unapproved peptide products have not been assessed for safety, quality or effectiveness. In June 2026, the TGA and Australia’s Chief Medical Officer specifically named retatrutide among unapproved peptide products of concern. A September 2026 TGA investigation also found a vial sold as retatrutide that contained no retatrutide and instead contained undeclared semaglutide.

For Australian status, use the TGA and the Australian Register of Therapeutic Goods as the primary references rather than social-media claims or overseas product listings.

How this tracker is maintained

Elite Peps prioritises ClinicalTrials.gov records, regulator publications, peer-reviewed papers and sponsor trial disclosures. We record the source type because a registry update, a company topline announcement, a conference presentation and a peer-reviewed publication carry different evidentiary weight. We also avoid ranking drugs by raw weight-loss percentages taken from unrelated trials.

Related research guides

For interpretation rather than news tracking, see how to read weight-loss clinical trial results. For the direct head-to-head evidence, see our SURMOUNT-5 tirzepatide vs semaglutide analysis. For retatrutide specifically, see the retatrutide Phase 3 trial tracker. Australian approved-medicine context is covered in our GLP-1 medicines in Australia guide.